Characterization of the Microbiome in Colonized Dystrophic and Junctional Epidermolysis Bullosa Wounds Before and After Use of APR-TD011 ® Spray Solution
Key facts
- Who runs it
- Northwestern University
- Where
- Chicago, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Early phase 1
- People taking part
- 15 people enrolled
- Started
- 6 Feb 2023
- Ended
- 31 Mar 2025
- Type of study
- Interventional
- Treatments tested
- APR-TD011
- Record updated
- 27 April 2025
Who can take part
- Age
- 6 months and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Patients 6 months of age or above with junctional or dystrophic epidermolysis bullosa
- Target wound that has been present for at least 3 weeks and is at least 10 cm2
- Target wound that is colonized with Staphylococcus aureus and/or Pseudomonas aeruginosa
Who cannot take part
- Patients currently or recently (within past 4 weeks) on topical or systemic antibiotics
- Do not agree to avoid bathing or topical application at the target starting the night before the visit
- Do not agree to avoid dilute bleach or vinegar baths, or other antiseptic use, at the target site starting at screening throughout the study
Where in United States
- Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United States
About the trial
What the trial wants to find out
In this pilot study, APR-TD011 antimicrobial wound cleansing spray will be given to all enrolled patients with junctional EB (JEB) or dystrophic epidermolysis bullosa (DEB) with Staphylococcus aureus or Pseudomonas aeruginosa culture-positive wounds. The primary aim will be to evaluate the change in skin microbiome (S. aureus, P. aeruginosa, commensal organisms) before, during, after treatment. Subjects who are colonized by S. aureus or pseudomonas will be treated for 8 weeks, will stop the spray and return at 12 weeks (4 weeks without the spray), and then will be able to use the spray as desired in a 6-month period of open-label use, with further feedback collected.
The group in the trial
- EB participantsTreatment being tested
Visits will include screening, pre-treatment (week 0), weeks 4 and 8, followed by a visit without use of the APR-TD011 for 4 weeks (week 12) for microbiome assessment off of therapy.
Treatment: APR-TD011
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 27 April 2025